Remembering one of the good guys in biotech

Mark Schoenebaum, a superlatively well-respected biotech analyst, died over the weekend. He was 46.

What endeared people to Schoenebaum, according to STAT’s Adam Feuerstein, was not just his aptitude and encyclopedic mind for the drug industry but also his warmth, humor, and generosity.

“I’m heading into my 20th year covering biotech, which makes me 1) very old, but 2) uniquely qualified to place Mark’s Wall Street career in its proper perspective,” Adam writes. “So, I say this without a hint of hyperbole: Mark was the most influential sell-side analyst that I’ve ever known.”

Read more.